Earnings call NEXGEL posts record revenue in Q3 2024 amid growth initiatives
| STAA Stock | USD 18.08 0.84 4.44% |
About 62% of STAAR Surgical's investor base is looking to short. The analysis of overall sentiment of trading STAAR Surgical stock suggests that many investors are alarmed at this time. The current market sentiment, together with STAAR Surgical's historical and current headlines, can help investors time the market. In addition, many technical investors use STAAR Surgical stock news signals to limit their universe of possible portfolio assets.
Earnings call NEXGEL posts record revenue in Q3 2024 amid growth initiatives
Read at investing.com
 |
STAAR Surgical Fundamental Analysis
We analyze STAAR Surgical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of STAAR Surgical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of STAAR Surgical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
STAAR Surgical is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
STAAR Surgical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with STAAR Surgical stock to make a market-neutral strategy. Peer analysis of STAAR Surgical could also be used in its relative valuation, which is a method of valuing STAAR Surgical by comparing valuation metrics with similar companies.
Peers
STAAR Surgical Related Equities
| NVST | Envista Holdings | 7.66 | ||||
| ANGO | AngioDynamics | 5.66 | ||||
| MBOT | Microbot Medical | 4.81 | ||||
| HOLX | Hologic | 2.48 | ||||
| ATR | AptarGroup | 1.42 | ||||
| WST | West Pharmaceutical | 0.18 | ||||
| HAE | Haemonetics | 0.56 | ||||
| COO | Cooper Companies, | 0.58 | ||||
| RMD | ResMed | 0.59 | ||||
| BDX | Becton Dickinson | 0.86 | ||||
| RGEN | Repligen | 1.11 | ||||
| ICUI | ICU Medical | 1.51 | ||||
| MMSI | Merit Medical | 2.15 |
Complementary Tools for STAAR Stock analysis
When running STAAR Surgical's price analysis, check to measure STAAR Surgical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy STAAR Surgical is operating at the current time. Most of STAAR Surgical's value examination focuses on studying past and present price action to predict the probability of STAAR Surgical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move STAAR Surgical's price. Additionally, you may evaluate how the addition of STAAR Surgical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |